Abstract: Objective To evaluate the efficacy and safety of combination therapy of oxaliplatin and S1 vs oxaliplatin and docetaxel for advanced gastric cancer (AGC) patients. Methods From April 2011 to January 2013, 62 cases of AGC were collected in the Fifth People′s Hospital of Qinghai Province. All cases were randomly divided into group A (31 cases) and B (31 cases) by random number table. In group A, oxaliplatin plus S-1 was administered, and in group B, oxaliplatin plus docetaxel was applied. The response rate (RR), time of diseases controlled rate (DCR), progressionfree survival (PFS), overall survival (OS) and adverse reactions of the two groups were observed and compared. Results There were no statistically differences between group A and group B in RR (48.4% vs 54.8%), DCR (67.7% vs 77.4%), mPFS (5.4 months vs 6.2 months), mOS (9.0 months vs 9.8 months), and the statistical values were as follows: χ2=0.26, P=0.711; χ2 =0.73, P=0.393; χ2=0.51, P=0.473; χ2=0.03, P=0.829. The incidence of degrees Ⅰ-Ⅱ peripheral neuropathy (9.7% vs 22.6%), nausea and vomiting (12.9% vs 32.3%) in group A were significantly lower than those in group B (χ2=5.78, P=0.002; χ2=4.63, P=0.016). Conclusion Both the two chemotherapies are similar in therapeutic effect for patients with AGC. Oxaliplatin plus S-1 treatment may be better than oxaliplatin plus docetaxel in the tolerance of patients.

Key words: Stomach neoplasms, Drug therapy, Oxaliplatin, Docetaxel, S-1